Qualigen Therapeutics Inc

Change company Symbol lookup

Select an option...

QLGN Qualigen Therapeutics Inc

PTA Cohen & Steers Tax-adv Prd Sec and Inc

FBK FB Financial Corp

DLY DoubleLine Yield Opportunities Fund

APTO Aptose Biosciences Inc

JQC Nuveen Credit Strategies Income Fund

GAB Gabelli Equity Trust

AMSF Amerisafe Inc

CLNE Clean Energy Fuels Corp

HUM Humana Inc

Go

Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer. The Company's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.